Top

Published in:

01-02-2005 | Original Article

Effects of tamoxifen on Doppler velocimetry parameters of periurethral vessels in postmenopausal women

Authors: Carlos A. Faria, Marair G. F. Sartori, Edmund C. Baracat, Geraldo Rodrigues de Lima, Manoel J. B. C. Girão

Published in: International Urogynecology Journal | Issue 1/2005

Abstract

The purpose of the present study was to assess the effect of tamoxifen on periurethral vessels by Doppler velocimetry examination. Increase in the number of these vessels as well as decrease in resistance and pulsatility indices by tamoxifen were observed.

Klutke JJ, Bergman A (1995) Hormonal influence on the urinary tract. Urol Clin North Am 22:629–639

Sartori MGF, Baracat EC, Girão MJBC, et al. (1995) Menopausal genuine stress urinary incontinence treated with conjugated estrogens plus progestogens. Int J Gynaecol Obstet 49:165–169CrossRefPubMed

Greene JL, Gilna P, Waterfield M, Baker A, et al. (1986) Sequence and expression of human estrogen receptor complementary DNA. Science 231:1150–1154PubMed

Kuiper GGJM, Enmark E, Pelto-Huikko M, et al. (1996) Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 93:5925–5930

Mosselman S, Polman J, Dijkema R (1996) ER β: identification and characterization of a novel human estrogen receptor. FEBS Lett 392:49–53CrossRefPubMed

Ogawa S, Inoue S, Watanabe T, et al. (1998) The complete primary structure of human estrogen receptor β (hERβ) and its heterodimerization with ER α in vivo and in vitro. Biochem Biophys Res Commun 243:122–126

Iosif CS, Batra S, Ek A, et al. (1981) Estrogen receptor in the human female lower urinary tract. Am J Obstet Gynecol 141:817–820PubMed

Suguita M, Girão MJBC, Simões MJA, et al. (2000) A morphologic and morphometric study of the vesical mucosa and urethra of castrated female rats following estrogen and/or progestogen replacement. Clin Exp Obstet Gynecol 27:176–178PubMed

Endo RM, Girão MJBC, Sartori MGF, et al. (2000) Effect of estrogen-progestogen hormonal replacement therapy on periurethral and bladder vessels. Int Urogynecol J 11:120–123CrossRef

10.

Raz S, Caine M, Zeigler M (1972) The vascular component in the production of intraurethral pressure. J Urol 108:93–96PubMed

11.

Rud T, Andersson KE, Asmussen M, et al. (1980) Factors maintaining the intraurethral pressure in women. Invest Urol (Berl) 17:343–347

12.

Gosling RG, Dumbar G, King DH, et al. (1971) The quantitative analysis of occlusive peripheral arterial disease by a non-intrusive ultrasonic technique. Angiology 22:52–55PubMed

13.

Pourcelot L (1975) Indications de l’ultrasonographie doppler dans l’etude des vaisseaux périphériques. Rev Prat 25:4671–4680PubMed

14.

Stuart B, Drumm J, Fitzgerald DE, et al. (1980) Fetal blood velocity waveforms in normal pregnancy. Br J Obstet Gynecol 87:780–785

15.

Jármy-Di Bella ZIK, Girão MJBC, Sartori MGF, et al. (2000) Power Doppler of the urethra in continent or incontinent, pre and postmenopausal women. Int Urogynecol J 11:148–155

16.

Girão MJBC, Jármy-Di Bella ZIK, Sartori MGF, et al. (2001) Dopplervelocimetry parameters of periurethral vessels in postmenopausal incontinent women receiving estrogen replacement. Int Urogynecol J 12:241–246

17.

Goldstein SR (1998) Selective estrogen receptor modulators: a new category of therapeutic agents for extending the health of postmenopausal women. Am J Obstet Gynecol 179:1479–1484PubMed

18.

Jordan VC (1997) Tamoxifen: the herald of a new era of preventive therapeutics. J Natl Cancer Inst 89:747–749CrossRefPubMed

19.

Iosif CS, al-Hijji J, Samsioe G (2002) Effects of tamoxifen and estradiol on estrogen binding sites in the urogenital tract: an experimental study in the rabbit. Gynecol Endocrinol 16:379–383PubMed

20.

Vardy M, Lindsay R, Scotti R, et al. (2003) Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. Am J Obstet Gynecol 189:81–88CrossRefPubMed

21.

Iguchi T, Hirokawa M, Takasugi N (1986) Occurrence of genital tract abnormalities and bladder hernia in female mice exposed neonattaly to tamoxifen. Toxicology 42:1-11CrossRefPubMed

22.

Fisher B, Constantini JP, Redmond CK, et al. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527–537CrossRefPubMed

23.

Fraiser LH, Kanekal S, Kehrer, JP (1991) Cyclophosphamide toxicity—characterising and avoiding the problem. Drugs 42:781–795PubMed

24.

Marks LB, Carrol PR, Dugen TC, et al. (1995) The response of the urinary bladder, urethra and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 31:1257–1280CrossRefPubMed

25.

Caetano JPL, Faria MML, Lins RM, et al. (1996) Princípios básicos e aplicações da dopplervelocimetria em ginecologia e obstetrícia. J Bras Ginecol 106:233–242

Title: Effects of tamoxifen on Doppler velocimetry parameters of periurethral vessels in postmenopausal women
Authors: Carlos A. Faria
Marair G. F. Sartori
Edmund C. Baracat
Geraldo Rodrigues de Lima
Manoel J. B. C. Girão
Publication date: 01-02-2005
Publisher: Springer-Verlag
Published in: International Urogynecology Journal / Issue 1/2005
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-004-1212-2

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Effects of tamoxifen on Doppler velocimetry parameters of periurethral vessels in postmenopausal women

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2005

Laparoscopic colposuspension versus urethropexy: a case-control series

Do subjective symptoms of obstructive voiding correlate with post-void residual urine volume in women?

PelviSoft BioMesh augmentation of rectocele repair: the initial clinical experience in 35 patients

The repeatability of the 24-hour pad test

Women’s Health Initiative data—what were the real conclusions and how will these studies impact the pelvic floor?

A comparison of outcomes of transurethral versus suprapubic catheterization after Burch cystourethropexy